A prediction model for early death in non-small cell lung cancer patients following curative-intent chemoradiotherapy.

"Disclosure statement: A.D. is funded by Varian Medical systems for projects other than the one described in this study."

"Funding This work was supported by the Interreg grant euroCAT and the Dutch Technology Foundation STW [DuCAT, grant no. 10696; Radiomics STRaTegy, grant no. P14–19], which is the applied science division of Nederlandse Organisatie voor Wetenschappelijk Onderzoek (NWO); the Technology Programme of the Ministry of Economic Affairs; and the Cancer Research UK Manchester Centre grants (C147/A18083) and (C147/ A25254). The authors also acknowledge financial support from the EU 7th framework program [ARTFORCE, grant no. 257144, REQUITE, grant no. 601826], CTMM-TraIT, EUROSTARS (CloudAtlas), Kankeronderzoekfonds Limburg from the Health Foundation Limburg, Alpe d’HuZes-KWF (DESIGN), The Dutch Cancer Society, NIH P01 CA059827, the European Program H2020–2015-17 [ImmunoSABR, grant no. 733008], the ERC advanced grant [ERC-ADG-2015, grant no. 694812; Hypoximmuno], SME Phase 2 (EU proposal 673780, RAIL)."